The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:1
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [31] Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors
    Dhall, Deepti
    Mertens, Richard
    Bresee, Catherine
    Parakh, Rugvedita
    Wang, Hanlin L.
    Li, Marissa
    Dhall, Girish
    Colquhoun, Steven D.
    Ines, Delma
    Chung, Fai
    Yu, Run
    Nissen, Nicholas N.
    Wolin, Edward
    HUMAN PATHOLOGY, 2012, 43 (04) : 489 - 495
  • [32] Prolonged Progression-Free Survival with Extended Cycle Streptozotozin/5-FU Chemotherapy in Patients with Metastatic Pancreatic Neuroendocrine Tumors
    Schrader, J.
    Zimmermann-Fraedrich, K.
    Benten, D.
    Pace, A.
    Blaeker, M.
    Lohse, A. W.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 269 - 269
  • [33] The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors.
    Delavault, Patrick
    Caplin, Martyn E.
    Liyange, Nilani
    Blumberg, Joelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Progression-free survival ratio and the implications for treatment sequencing in neuroendocrine neoplasms
    Melhorn, P.
    Kretschmer-Chott, E.
    Mazal, P.
    Raderer, M.
    Kiesewetter-Wiederkehr, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S758 - S758
  • [35] Relationship between lanreotide autogel, chromogranin A and progression-free survival in patients with gastroenteropancreatic neuroendocrine tumours
    Buil-Bruna, N.
    Dehez, M.
    Manon, A.
    Xuan, Q. N. Thi
    Troconiz, I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S448 - S448
  • [36] Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
    Faivre, S.
    Niccoli, P.
    Castellano, D.
    Valle, J. W.
    Hammel, P.
    Raoul, J. -L.
    Vinik, A.
    Van Cutsem, E.
    Bang, Y. -J.
    Lee, S. -H.
    Borbath, I.
    Lombard-Bohas, C.
    Metrakos, P.
    Smith, D.
    Chen, J. -S.
    Ruszniewski, P.
    Seitz, J. -F.
    Patyna, S.
    Lu, D. R.
    Ishak, K. J.
    Raymond, E.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 339 - 343
  • [37] Nomogram to Predict Progression-free Survival in Patients with Well-differentiated, Stage IV Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues: Data of TRASGU-GETNE Study
    Jimenez-Fonseca, P.
    Alonso, V
    Riesco, M. C.
    Custodio, A.
    Molina-Cerrillo, J.
    Sanchez Canovas, M.
    Benavent, M.
    Hernando Cubero, J.
    La Casta, A.
    Lopez, C.
    Marazuela Azpiroz, M.
    Carmona-Bayonas, A.
    NEUROENDOCRINOLOGY, 2019, 108 : 67 - 67
  • [38] Levels of Uninvolved Immunoglobulin Predict Clinical Status and Progression-Free Survival for Multiple Myeloma Patients
    Harutyunyan, Nika M.
    Vardanyan, Suzie
    Ghermezi, Michael
    Gottlieb, Jillian
    Berenson, Ariana
    Andreu-Vieyra, Claudia
    Tang, George
    Sanchez, Eric
    Li, Mingjie
    Wang, Cathy
    Ben-Zvi, Joseph
    Garzio, Gigi
    Chen, Haiming
    Finlay, Judith
    Berenson, James R.
    BLOOD, 2014, 124 (21)
  • [39] Development of a nomogram to predict progression-free survival in patients with locally advanced renal cell carcinoma
    Xiao, Ruo-Tao
    Liu, Cheng
    Yang, Bin
    He, Wei
    Xu, Chu-Xiao
    Chen, Zhi-Gang
    Ma, Lu-Lin
    CHINESE MEDICAL JOURNAL, 2021, 134 (22) : 2765 - 2767
  • [40] Procalcitonin Levels Predict Clinical Course and Progression-Free Survival in Patients With Medullary Thyroid Cancer
    Walter, Martin A.
    Meier, Christian
    Radimerski, Tanja
    Iten, Fabienne
    Kraenzlin, Marius
    Mueller-Brand, Jan
    de Groot, Jan Willem B.
    Kema, Ido P.
    Links, Thera P.
    Mueller, Beat
    CANCER, 2010, 116 (01) : 31 - 40